Effect of nifedipine on severe experimental cataract in diabetic rats

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 651-658

  Kametaka, Sokichi ^a   Kasahara, Takafumi ^a   Ueo, Mayumi ^a   Takenaka, Mariko ^a   Saito, Maki ^a   Sakamoto, Kenji ^a   Nakahara, Tsutomu ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Cataract; Diabetes; L type Ca2+ channel; Lens; Streptozotocin

Indexed keywords

GLUCOSE; NIFEDIPINE; STREPTOZOCIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAMERA; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIGITAL IMAGING; DISEASE DURATION; DRUG EFFECT; HYPERGLYCEMIA; LENS; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

EID: 42349090384     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0072294     Document Type: Article

References (42)

1. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet. 1976;2:1009-1012.
2. Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology. 1985;92:1191-1196.
3. Jahn CE, Janke M, Winowski H, von Bergmann K, Leiss O, Hockwin O. Identification of Metabolic Risk Factors for Posterior Subcapsular Cataract. Ophthalmic Res. 1986;18:112-116.
4. Brown NP, Bron AJ. Aetiological classification of cataract: Ocular toxic, nutritional and physical factors, and senile cataract. In; Brown NP, Bron AJ, editors. Lens Disorders a Clinical Manual of Cataract Diagnosis. Oxford: Butterwoth-Heinemann; 1996. p. 190-211.
5. Swamy-Mruthinti S, Shaw SM, Zhao HR, Green K, Abraham EC. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr Eye Res. 1999;18:423-429.
6. Kinoshita JH, Kador PF, Catiles M. Aldose reductase in diabetic cataracts. JAMA. 1981;246:257-261.
7. Kador PF, Akagi Y, Kinoshita JH. The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism. 1986;35:15-19.
8. Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn J Pharmacol. 1997;73:133-144.
9. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999;13:23-30.
10. Banditelli S, Boldrini E, Vilardo PG, Cecconi I, Cappiello M, Dal Monte M, et al. A new approach against sugar cataract through aldose reductase inhibitors. Exp Eye Res. 1999;69:533-538.
11. Kubo E, Miyoshi N, Fukuda M, Akagi Y. Cataract formation through the polyol pathway is associated with free radical production. Exp Eye Res. 1999;68:457-464.
12. Lyons TJ, Silvestri G, Dunn JA, Dyer DG, Baynes JW. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. Diabetes. 1991;40:1010-1015.
13. Duhaiman AS. Glycation of human lens proteins from diabetic and (nondiabetic) senile cataract patients. Glycoconj J. 1995;12:618-621.
14. Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism. 1999;48:1141-1145.
15. Spector A. Oxidative stress and disease. J Ocul Pharmacol Ther. 2000;16:193-201.
16. Boscia F, Grattagliano I, Vendemiale G, Micelli-Ferrari T, Altomare E. Protein oxidation and lens opacity in humans. Invest Ophthalmol Vis Sci. 2000;41:2461-2465.
17. Ozmen B, Ozmen D, Erkin E, Guner I, Habif S, Bayindir O. Lens superoxide dismutase and catalase activities in diabetic cataract. Clin Biochem. 2002;35:69-72.
18. 2+ exchanger during cataractogenesis in diabetic rats. J Diabetes Complications. 2004;18:177-182.
19. Duncan G, Bushell AR. Ion analyses of human cataractous lenses. Exp Eye Res. 1975;20:223-230.
20. Pierce GN, Afzal N, Kroeger EA, Lockwood MK, Kutryk MJ, Eckhert CD, et al. Cataract formation is prevented by administration of verapamil to diabetic rats. Endocrinology. 1989;125:730-735.
21. Hightower KR, Riley MV, McCready J. Regional distribution of calcium in alloxan diabetic rabbit lens. Curr Eye Res. 1989;8:517-522.
22. Fleckenstein A. Prevention by verapamil of arterial calcium overload and concomitant lenticular calcification causing cataracts in alloxan-diabetic rats. In: Calcium antagonism in heart and smooth muscle: Experimental facts and therapeutic prospects. New York: John Wiley and Sons; 1983. p. 280-285.
23. Ettl A, Daxer A, Gottinger W, Schmid E. Inhibition of experimental diabetic cataract by topical administration of RS-verapamil hydrochloride. Br J Ophthalmol. 2004;88:44-47.
24. Cekic O, Bardak Y. Lenticular Calcium, Magnesium, and Iron Levels in Diabetic Rats and Verapamil Effect. Ophthalmic Res. 1998;30:107-112.
25. Azuma M, Shearer TR, Matsumoto T, David LL, Murachi T. Calpain II in two in vivo models of sugar cataract. Exp Eye Res. 1990;51:393-401.
26. Gandolfi SA, Duncan G, Tomlinson J, Maraini G. Mammalian lens inter-fiber resistance is modulated by calcium and calmodulin. Curr Eye Res. 1990;9:533-541.
27. Sanderson J, Gandolfi SA, Duncan G. Calmodulin antagonists induce changes in lens permeability and transparency. Curr Eye Res. 1994;13:219-224.
28. Truscott RJ, Marcantonio JM, Tomlinson J, Duncan G. Calcium-induced cleavage and breakdown of spectrin in the rat lens. Biochem Biophys Res Commun. 1989;162: 1472-1477.
29. 2+-induced protein loss, vimentin cleavage and opacification. Invest Ophthalmol Vis Sci. 2000;41:2255-2261.
30. Giblin FJ, Hightower KR, Ragatzki PA, Reddy VN. Calcium-induced high molecular weight proteins in the intact rabbit lens. Exp Eye Res. 1984;39:9-17.
31. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res. 1990;66:1449-1452.
32. Kametaka S, Kasahara T, Ueo M, Takenaka M, Saito M, Sakamoto K, et al. A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats. J Pharmacol Sci. 2008;106:144-151.
33. Chylack LT Jr, Leske MC, Sperduto R, Khu P, McCarthy D. Lens Opacities Classification System. Arch Ophthalmol. 1988;106:330-334.
34. Leske MC, Chylack LT Jr, Sperduto R, Khu P, Wu SY, McCarthy D. Evaluation of a Lens Opacities Classification System. Arch Ophthalmol. 1988;106:327-329.
35. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, et al. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism. 1991;40:77-87.
36. Suryanarayana P, Krishnaswamy K, Reddy GB. Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis. 2003;9:223-230.
37. Wang L, Bhatnagar A, Ansari NH, Dhir P, Srivastava SK. Mechanism of calcium-induced disintegrative globulization of rat lens fiber cells. Invest Ophthalmol Vis Sci. 1996; 37:915-922.
38. Srivastava SK, Wang LF, Ansari NH, Bhatnagar A. Calcium homeostasis of isolated single cortical fibers of rat lens. Invest Ophthalmol Vis Sci. 1997;38:2300-2312.
39. Thomas GR, Duncan G, Sanderson J. Acetylcholine-induced membrane potential oscillations in the intact lens. Invest Ophthalmol Vis Sci. 1998;39:111-119.
40. Devamanoharan PS, Varma SD. Inhibition of polyol formation in rat lens by verapamil. J Ocul Pharmacol Ther. 1995;11:527-531.
41. Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res. 2004;30:169-175.
42. van Heyningen R, Harding JJ. Do aspirin-like analgesics protect against cataract? A case-control study. Lancet. 1986;17:1111-1113.